ProBiotix Health Plc

ProBiotix Health develops probiotics (live microbes that, when ingested, can alter the composition of the microbiome and improve human health) to tackle cardiovascular disease and other lifestyle conditions which are affecting growing numbers of people across the world. ProBiotix Health’s cholesterol reducing probiotic, Lactobacillus plantarum ECGC13110402 (“LP-LDL®), is manufactured in pharmaceutical GMP-certified facilities and protected worldwide by in the region of 5 patent families, comprising 27 patents and pending patent applications, and 22 trademarks.

Important notice

The products and services shown on this website place capital at risk. Investors may receive less in returns than they have invested. Investments may not allow for capital to be withdrawn on demand. If an investment provides tax relief then this relief is subject to change and is dependant on personal circumstances. Any reference to past performance or forecasted performance is not a reliable indicator of future performance.

Seneca Partners recommends that any investor seeks specialised financial and/or tax advice before investing. Seneca Partners does not provide advice and the information on this website, including but not limited to news, should not be construed as such.

Please confirm that you understand this warning and wish to proceed.